The market size exceeds 50 billion! Another hemodialysis giant plans to go public

合壹滙科技Jun 28, 2022 15:53

IPO | Weigao Blood Purification, a leading company in the Chinese blood purification market, submitted the list to the Hong Kong Stock Exchange

On June 28, Capital Bank learned that Shandong Weigao Blood Purification Products Co., Ltd. submitted a listing to the main board of the Hong Kong Stock Exchange, with Citigroup, Huatai International and Huaxing Capital as co-sponsors. According to the prospectus, the company is a leading enterprise in the Chinese blood purification market. It is in a leading position in all major tracks in the field of blood purification, leading domestic substitution. In 2021, the company's dialyzer sales accounted for 32.4%, ranking first in the country, and blood pipeline sales accounted for 32.6%, ranking first in the country and far exceeding second place. The sales of hemodialysis machines sold exclusively domestically accounted for the total sales of domestic hemodialysis machines

ChinaIPO NewsJun 28, 2022 14:50

Vigor Blood Purification Submits Listing Application

Veigor's blood purification submits a listing application to the Stock Exchange with the joint sponsors Citi, Huatai International and Huaxing Capital. Earlier, external news said that Weigao's blood purification target raised about $500 million. The company mainly provides comprehensive blood purification products, including dialyzer, dialysis machine, blood line and other hemodialysis products, peritoneal dialysis products such as peritoneal dialysis. Currently, there are 219 self-developed hemodialysis products. According to market research institutes, the company's dialyzer sales market share in 2021 was 32.4% and blood pipeline sales market share of 32.6%, ranked first in the Mainland market. Initial IPO

即市頭條Jun 28, 2022 10:04

New stock news | Vega Blood purification delivery form HKEx is the leading company in China's blood purification market.

Shandong Weigao Blood purification products Co., Ltd. submitted an application for listing to the Hong Kong Stock Exchange, with Citigroup, Huatai International and China Renaissance Capital Investment as its co-sponsors, Zhitong Financial APP learned. According to the prospectus, China's blood purification market has a huge base, rapid growth and huge growth potential. As a leading enterprise, Weigao Blood purification is in a leading position in all major tracks in the field of blood purification, leading domestic substitutes. The number of patients with end-stage renal disease (ESRD) in China is huge, reaching 3.59 million in 2021. According to Frost Sullivan's forecast, the number of ESRD patients in China in 2026

Zhitong FinanceJun 27, 2022 22:43

The technical difficulties have not been solved, and profit space is limited. Where is the path for domestic hemodialysis companies?

Only by cracking the “stuck neck” technology can domestic brands make a comeback in the collection

財經大健康Jun 21, 2022 17:41

Lu Zhishen｜The “Weigao Phenomenon” in the capital market

魯網Jun 17, 2022 17:23